Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161011 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Controlled Study of Dosing Techniques - Part B
A Phase 2 study of Dry Eye, sponsored by IVIEW Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07161011 is a Phase 2 study of Dry Eye that is active but no longer recruiting, run by IVIEW Therapeutics. The registered enrollment target is 30 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07161011, a Phase 2 study of Dry Eye, is active but no longer recruiting, sponsored by IVIEW Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Double-masked, dose-response of two concentrations of IVW-1001
Conditions Studied
Interventions
- DRUG IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- DRUG IVW-1001 Ophthalmic Eyelid Wipe 0.4%
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07161011
The ClinicalTrials.gov registry entry for NCT07161011 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The listed sponsor is IVIEW Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which IVW-1001 Ophthalmic Eyelid Wipe 0.2% is the first listed.
NCT07161011 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07161011 about?
NCT07161011 is a clinical study titled "Phase 2b Controlled Study of Dosing Techniques - Part B". Double-masked, dose-response of two concentrations of IVW-1001
What is the current status of trial NCT07161011?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-08. Estimated completion is 2025-12-31.
What conditions does trial NCT07161011 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT07161011?
The interventions under investigation include: IVW-1001 Ophthalmic Eyelid Wipe 0.2% (DRUG), IVW-1001 Ophthalmic Eyelid Wipe 0.4% (DRUG).
Who is sponsoring clinical trial NCT07161011?
This trial is sponsored by IVIEW Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161011 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.